Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
June 21 2019 - 3:30PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced the closing of its
previously announced underwritten public offering of common stock,
including the exercise in full by the underwriters of their option
to purchase an additional 885,000 shares at the public offering
price of $17.00 per share. The exercise of the option to purchase
additional shares brought the total number of shares of common
stock sold by Kura to 6,785,000 shares and increased the amount of
gross proceeds raised in the offering, before underwriting
discounts and estimated expenses of the offering payable by Kura,
to approximately $115.3 million.
SVB Leerink and Cowen acted as joint book-running managers for
the offering. Wedbush PacGrow and Oppenheimer & Co. acted as
co-lead managers, and H.C. Wainwright & Co. acted as co-manager
for the offering.
The securities described above were offered by Kura pursuant to
a shelf registration statement on Form S-3, including a base
prospectus, that was previously filed by Kura with the Securities
and Exchange Commission (the “SEC”) and that was declared effective
on November 21, 2018. A final prospectus supplement and the
accompanying prospectus relating to the offering have been filed
with the SEC and are available for free on the SEC’s website
located at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may be obtained from SVB Leerink LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110, by
telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com, or Cowen and Company, LLC c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717,
Attention: Prospectus Department, or by telephone at (631)
592-5973, or by email at PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. Kura’s pipeline consists of small molecule
drug candidates that target cancer signaling pathways where there
is a strong scientific and clinical rationale to improve outcomes
by identifying those patients most likely to benefit from
treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl
transferase inhibitor, for which Kura has initiated a
registration-directed trial in recurrent or metastatic patients
with HRAS mutant HNSCC. In addition, tipifarnib is being evaluated
in multiple other Phase 2 clinical trials in solid tumor and
hematologic indications. Kura’s pipeline also includes KO-947, an
ERK inhibitor, currently in a Phase 1 dose-escalation trial, and
KO-539, a menin-MLL inhibitor, which has been cleared to begin a
Phase 1 clinical trial.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024